

Supporting Information

THE PRACTICAL SYNTHESIS OF DISSYMMETRICAL 1,3,5-TRIOXAZATRIQUINANE DERIVATIVES COMPRISED OF THREE DISTINCT CARBONYL COMPOUNDS

Shigeto Hirayama,^{1,2} Koji Obayashi,¹ Naohisa Wada,¹ Kousuke Ohyama,¹ Shizuho Fuku,¹ Koji Koyano,¹ Fumika Karaki,^{1,2} Kennosuke Itoh,^{1,2} Hiroshi Nagase,³ and Hideaki Fujii^{1,2,*}


¹Laboratry of Medicinal Chemistry, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan; ²Medicinal Research Laboratories, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan; ³International Institute for Integrative Sleep Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan; E-mail: fujiih@pharm.kitasato-u.ac.jp

TABLE OF CONTENTS


Synthetic methods of 1,3,5-trioxazatriquinane derivatives	S1
Synthesis of protected α -hydroxyaldehyde 29 with PMB group	S4
Synthesis of free α -hydroxyaldehyde 30	S5
Determination of the relative configurations of 1,3,5-trioxazatriquinanes 19 and 33	S6
References	S7

Synthetic methods of 1,3,5-trioxazatriquinane derivatives

We have already reported the synthesis of symmetrical 1,3,5-trioxazatriquinane derivatives.¹⁻⁶ A general synthetic scheme is shown in Scheme S1. α -Hydroxyaldehyde **S1** prepared from the corresponding ketone^{1,2} was converted into oxazoline **S2**. A solution of **S2** in CHCl₃ was refluxed in the presence of CSA to provide symmetrical 1,3,5-trioxazatriquinane **S3**.¹ The results suggested that a part of oxazoline **S2** was hydrolyzed to give α -hydroxyaldehyde **S1** during the reaction and that **S2** reacted with **S1** prepared *in situ* to provide **S3**. A trace amount of water in the reaction system may catalyze the reaction. The specific example¹ is indicated in Scheme S2.




Scheme S1. General synthetic method of symmetrical 1,3,5-trioxazatriquinane **S3**




Scheme S2. Specific example of synthesis of symmetrical 1,3,5-trioxazatriquinane¹

The intermediate oxazoline **S2** could be isolated, which enabled the reaction of **S2** and a second α -hydroxyaldehyde **S1'**. Therefore, dissymmetrical 1,3,5-trioxazatriquinanes **S3'** was selectively obtained (Scheme S3).¹⁻³ The results suggested that the reaction rate of **S1'** with **S2** would be faster than that of hydrolysis of **S2** in the presence of a catalytic amount of water. The specific example³ was delineated in Scheme S4.




Scheme S3. General synthetic method of dissymmetrical 1,3,5-trioxazatriquinane **S3'**




Scheme S4. Specific example of synthesis of dissymmetrical 1,3,5-trioxazatriquinane³

Taking into account the results mentioned above, in order to selectively synthesize dissymmetrical 1,3,5-trioxazatriquinanes **S3''** ($R^1 \neq R^3 \neq R^5$, $R^2 \neq R^4 \neq R^6$) it was key to obtain oxazolines **S2'** consisting of two distinct α -hydroxyaldehydes (Scheme S5).



Scheme S5. General synthetic method of dissymmetrical 1,3,5-trioxazatriquinane **S3''**


We have already reported oxazoline **S5** synthesized from **S4** and glycolaldehyde dimer (Scheme S6).⁴ Although we examined the reaction of **S4** with various α -hydroxyaldehydes, only the glycolaldehyde selectively gave the objective oxazoline. Oxazoline **S5** reacted with glycolaldehyde dimer to afford 1,3,5-trioxazatriquinanes **S6** and **S7**. However, the obtained 1,3,5-trioxazatriquinanes **S6** and **S7** were comprised of two glycolaldehydes (Scheme S6).⁴ We attempted to treat **S5** with α -hydroxyaldehyde **S8** to provide 1,3,5-trioxazatriquinane **S9**, which consisted of three distinct α -hydroxyaldehydes. Unfortunately, the yield was only 4.3% (unpublished results). The results suggested that oxazoline **S5** was easily hydrolyzed.



Scheme S6. Synthesis of oxazoline **S5** and dissymmetrical 1,3,5-trioxazatriquinanes **S6**, **S7**, and **S9**.


*The yields were calculated from the corresponding precursor ketone of **S4**

In theory, the reaction of two different α -hydroxyaldehydes **S1** and **S1'** could give the objective oxazoline **S2'**. However, oxazolines **S2**, **S2''**, and **S2'''** were also obtained concomitantly (Scheme S7). Moreover, each oxazoline has eight diastereomers. Therefore, this synthetic tactic was not practical.




Scheme S7. The reaction of two different α -hydroxyaldehydes **S1** and **S1'**

Synthesis of protected α -hydroxyaldehyde **29** with PMB group




2-((4-Methoxybenzyl)oxy)-2-(3-methoxyphenyl)propan-1-ol (S12)



Using the procedure for the preparation of **14**, **S12** (2.35 g, 15.9 mmol) was obtained from **S11**⁷ (2.35 g, 15.9 mmol) as a colorless oil in 58% yield.

HR-MS (ESI): $[M+Na]^+$ Calcd. For $C_{18}H_{22}NaO_4$: 325.1416. Found: 325.1419. IR (neat): 2937, 1611, 1514, 1487, 1290, 1249, 1173, 1037, 821, 704 cm^{-1} . 1H NMR (400 MHz, $CDCl_3$): δ 1.73 (s, 3H), 3.53 (d, $J = 11.2$ Hz, 1H), 3.73 (d, $J = 11.2$ Hz, 1H), 3.81 (s, 6H), 4.18 (d, $J = 10.6$ Hz, 1H), 4.32 (d, $J = 10.6$ Hz, 1H), 6.84-6.94 (m, 3H), 7.02-7.08 (m, 2H), 7.25-7.37 (m, 3H), a proton (OH) was not observed. ^{13}C NMR (100 MHz, $CDCl_3$): δ 20.0, 55.1, 55.2, 64.6, 71.6, 80.0, 112.6, 112.7, 113.8, 118.9, 129.1, 129.4, 130.8, 144.1, 159.1, 159.7.


2-((4-Methoxybenzyl)oxy)-2-(3-methoxyphenyl)propanal (29)




Using the procedure for the preparation of **16**, **29** (104 mg, 0.347 mmol) was obtained from **S12** (194 mg, 0.642 mmol) as a colorless oil in 69% yield.

HR-MS (ESI): $[M+Na]^+$ Calcd. for $C_{18}H_{20}NaO_4$: 323.1259. Found: 323.1249. IR (neat): 2937, 2835, 1733, 1611, 1514, 1252, 1173, 1131, 1034 cm^{-1} . 1H NMR (400 MHz, $CDCl_3$): δ 1.76 (s, 3H), 3.81 (s, 3H), 3.82 (s, 3H), 4.42 (s, 2H), 6.86-6.93 (m, 3H), 7.02-7.06 (m, 2H), 7.29-7.36 (m, 3H), 9.58 (s, 1H). ^{13}C NMR (100 MHz, $CDCl_3$): δ 18.7, 55.26, 55.29, 65.5, 84.1, 112.6, 113.7, 113.9, 119.1, 129.1, 129.9, 130.2, 139.7, 159.3, 160.1, 199.5.

Synthesis of free α -hydroxyaldehyde **30**



2-Hydroxy-2-phenylpropanal (**30**)




Using the reported procedure⁵, **30** (2.23 g, 14.9 mmol) was obtained from **S13** (3.00 g, 25.0 mmol) as a colorless oil in 54% yield.

All the physical data were identical to the reported data.⁸


Determination of the relative configurations of 1,3,5-trioxazatriquinanes **19** and **33**

The relative configurations of **19a-c** were determined by ROSEY and HMBC experiments.



Values in parentheses and brackets mean chemical shifts of ¹H NMR or ¹³C NMR, respectively.

The relative configurations of **33a-d** were determined by ROSEY and HMBC experiments.



Values in parentheses and brackets mean chemical shifts of ^1H NMR or ^{13}C NMR, respectively.

REFERENCES

1. H. Nagase, A. Watanabe, M. Harada, M. Nakajima, K. Hasebe, H. Mochizuki, K. Yoza, and H. Fujii, *Org. Lett.*, 2009, **11**, 539.
2. H. Nagase, K. Koyano, N. Wada, S. Hirayama, A. Watanabe, T. Nemoto, M. Nakajima, K. Nakao, H. Mochizuki, and H. Fujii, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 6198.
3. H. Nagase, A. Watanabe, T. Nemoto, M. Nakajima, K. Hasebe, H. Mochizuki, and H. Fujii, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 4023.
4. N. Wada, H. Fujii, K. Koyano, S. Hirayama, T. Iwai, T. Nemoto, and H. Nagase, *Bioorg. Med. Chem. Lett.*, 2012, **22**, 7551
5. S. Hirayama, N. Wada, T. Nemoto, T. Iwai, H. Fujii, and H. Nagase, *ACS. Med. Chem. Lett.* 2014, **5**, 868.
6. S. Hirayama, N. Wada, N. Kuroda, T. Iwai, N. Yamaotsu, S. Hirono, H. Fujii, and H. Nagase, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 4895.
7. A. Fryszkowska, K. Fisher, J. M. Gardiner, and G. M. Stephens, *J. Org. Chem.*, 2008, **73**, 4295.

8. D. Bojer, I. Kamps, X. Tian, A. Hepp, T. Pape, R. Fröhlich, and N. W. Mitzel. *Angew. Chem. Int. Ed.*, 2007, **46**, 4176.